Thursday, December 26

Healthcare

Neurocrine stock dips even as schizophrenia drug meets main goal in study

08/29/20241 Min Read

dips drug goal main meets Neurocrine schizophrenia stock study

Previous ArticleShuttle Pharma regains compliance with Nasdaq minimum bid price requirement

Next Article Sonoma Pharmaceuticals to implement a reverse stock split